PAION to Present at Five Upcoming Conferences

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that it will be present at the following conferences:

Rodman & Renshaw Annual Global Investment ConferenceDate: Friday, 11 September, 2009Time: 10:00 a.m. EDT (04:00 p.m. CEST, 03:00 p.m. BST)Venue: New York, USAPresenter: Dr. Wolfgang S�hngen, CEO of PAION AG

German Healthcare ConferenceOrganizer: DZ Bank with Deutsche B�rse GroupDate: Friday, 11 September, 2009Time: 09:50 a.m. CEST (03:50 a.m. EDT, 08:50 a.m. BST)Venue: Zurich, SwitzerlandPresenter: Dr. Mariola S�hngen, CMO of PAION AG

UBS Global Life Sciences ConferenceDate: Tuesday, 22 September, 2009Time: 11:30 a.m. EDT (05:30 p.m. CEST, 04:30 p.m. BST)Venue: New York, USAPresenter: Dr. Wolfgang S�hngen, CEO of PAION AG

Bio Europe 2009Date: 2-4 November 2009Time: N/AVenue: Vienna, AustriaPresenter: To Be Announced

German Equity Forum Fall 2009Date: Tuesday, 10 November, 2009Time: 03:45 p.m. CET in Room Zurich (09:45 a.m. ET, 02:45 p.m. GMT)Venue: Frankfurt/Main, GermanyPresenters: Dr. Wolfgang S�hngen, CEO of PAION AGBernhard Hofer, CFO of PAION AG

###

About PAION PAION is a biopharmaceutical company headquartered in Aachen, Germany. Since the acquisition of CeNeS Pharmaceuticals, which was completed in June 2008, the company has a second site in Cambridge, UK. The company is specialized in developing and commercializing innovative drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need. PAION has a “Search & Develop” business model, which is based on its core expertise in drug development. Where appropriate, particularly during the late stages of the clinical development, PAION seeks to collaborate with experienced partners.